{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:22:56Z","timestamp":1789993376819,"version":"4.0.1"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T00:00:00Z","timestamp":1231113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Photodynamic therapy (PDT) using methyl aminolevulinate (MAL) is an effective first\u2010line treatment for actinic keratoses. A reduced incubation period may have practical advantages.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> This study aims to evaluate the effect of incubation time (1 vs. 3\u00a0h), MAL concentration (160\u00a0mg\/g vs. 80\u00a0mg\/g) and lesion preparation in the setting of MAL\u2010PDT for treatment of actinic keratosis (AK).<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Open, randomized, parallel\u2010group multicentre study.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Outpatient dermatology clinics.<\/jats:p><jats:p><jats:bold>Subjects\u2002<\/jats:bold> One hundred and twelve patients with 384 previously untreated AK. Most lesions (87%) were located on the face and scalp and were thin (55%) or moderately thick (34%).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Lesions were debrided, and MAL cream (160\u00a0mg\/g or 80\u00a0mg\/g) was applied before illumination with red light (570\u2013670\u00a0nm; light dose, 75\u00a0J\/cm<jats:sup>2<\/jats:sup>). Patients were followed up at 2 and 3\u00a0months. Sixty patients (54%) were re\u2010treated and assessed at 6\u00a0months.<\/jats:p><jats:p><jats:bold>Main outcome\u2002<\/jats:bold> Complete lesion response rates 3 and 12\u00a0months after last treatment.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> For lesions on the face\/scalp, lesion complete response rates were 78% for thin AK and 74% for moderately thick AK lesions after 1\u00a0h vs. 96% and 87% after 3\u00a0h incubation with MAL 160\u00a0mg\/g. Lesion recurrence rates at 12\u00a0months after two treatments were similar [19% (3 of 16) with 1\u00a0h vs. 17% (3 of 18) with 3\u00a0h 160\u00a0mg\/kg MAL\u2010PDT] and lower than for 80\u00a0mg\/g MAL\u2010PDT (44\u201345%).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> MAL\u2010PDT using a 1\u2010h incubation may be sufficient for successful treatment of selected AK lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflicts of interest<\/jats:title><jats:p>Lasse R Braathen consults for Photocure and has received speaker honoraria from Photocure and Galderma. Trond Warloe is a co\u2010inventor of the corresponding patent and is a minor share holder of Photocure ASA. Tore Morken has been paid as a chairman of a Photocure\u2010sponsored symposium. Bruno E Paredes, Olli Saksela, Clemens Fritsch, Kerstin Gardlo, Karin W Fr\u00f6lich, Ana M Sol\u00e9r and Ann\u2010Marie Ros do not have any relevant conflict of interest, financial or otherwise.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2008.03029.x","type":"journal-article","created":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T23:08:49Z","timestamp":1231196929000},"page":"550-555","source":"Crossref","is-referenced-by-count":57,"title":["Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses"],"prefix":"10.1111","volume":"23","author":[{"given":"LR","family":"Braathen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BE","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Saksela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Gardlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Morken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KW","family":"Fr\u00f8lich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Warloe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Sol\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u2010M","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91658-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680060103013"},{"key":"e_1_2_6_4_2","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth E","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.006"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.49"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630310012118"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.119649"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07470.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700048"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70113-G"},{"key":"e_1_2_6_12_2","unstructured":"National Cancer Institute.National Cancer Institute Common Toxicity Criteria version 2.0.30 April 1999."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.33"},{"key":"e_1_2_6_14_2","first-page":"629","article-title":"Short incubation PDT versus 5\u2010FU in treating actinic keratoses","volume":"2","author":"Smith S","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/1011-1344(95)90253-8"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.03029.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.03029.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:10:40Z","timestamp":1697062240000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.03029.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,3]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1468-3083.2008.03029.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.03029.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,3]]}}}